Delivery strategies of amphotericin B for invasive fungal infections

被引：3

作者：

Xiaochun Wang ^{[1
]}

Imran Shair Mohammad ^{[2
]}

Lifang Fan ^{[3
]}

Zongmin Zhao ^{[4
]}

Md Nurunnabi ^{[5
]}

Marwa A.Sallam ^{[6
]}

Jun Wu ^{[7
]}

Zhongjian Chen ^{[8
]}

Lifang Yin ^{[1
]}

Wei He ^{[1
]}

机构：

[1] Department of Pharmaceutics,China Pharmaceutical University

[2] School of Pharmaceutical Sciences,Sun Yat-sen University,University Town

[3] Jiangsu Aosaikang Pharmaceutical Co.,Ltd.

[4] School of Engineering and Applied Sciences,Harvard University

[5] Department of Pharmaceutical Sciences,School of Pharmacy,University of Texas at El Paso

[6] Department of Industrial Pharmacy,Faculty of Pharmacy,Alexandria University

[7] Department of Geriatric Cardiology,Jiangsu Provincial Key Laboratory of Geriatrics,the First Affiliated Hospital of Nanjing Medical University

[8] Shanghai Skin Disease Hospital,Tongji University School of Medicine

来源：

ActaPharmaceuticaSinicaB | 2021年 / 11卷 / 08期

基金：

中国国家自然科学基金;

关键词：

D O I：

暂无

中图分类号：

R943 [制剂学];

学科分类号：

摘要：

Invasive fungal infections(IFIs) represent a growing public concern for clinicians to manage in many medical settings, with substantial associated morbidities and mortalities. Among many current therapeutic options for the treatment of IFIs, amphotericin B(AmB) is the most frequently used drug.AmB is considered as a first-line drug in the clinic that has strong antifungal activity and less resistance.In this review, we summarized the most promising research efforts on nanocarriers for AmB delivery and highlighted their efficacy and safety for treating IFIs. We have also discussed the mechanism of actions of AmB, rationale for treating IFIs, and recent advances in formulating AmB for clinical use. Finally, this review discusses some practical considerations and provides recommendations for future studies in applying AmB for combating IFIs.

引用

页码：2585 / 2604

页数：20

共 50 条

[21] AMPHOTERICIN-B AND FUNGAL-INFECTIONS
BERNARD, S
INFECTIONS IN SURGERY, 1990, 9 (07): : 17 - 17
[22] Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia
Zhang Jinyu
Gong Yizhen
Wang Ke
Kong Jinliang
Chen Yiqiang
中华医学杂志（英文版）, 2014, 127 (04) : 753 - 757
[23] Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
Leenders, ACAP
Daenen, S
Jansen, RLH
Hop, WCJ
Lowenberg, B
Wijermans, PW
Cornelissen, J
Herbrecht, R
Van der Lelie, H
Hoogsteden, HC
Verbrugh, HA
de Marie, S
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) : 205 - 212
[24] BUDGET IMPACT ANALYSIS OF LIPOSOMAL AMPHOTERICIN B AND AMPHOTERICIN B LIPID COMPLEX FOR TREATING INVASIVE FUNGAL INFECTIONS IN HOSPITALIZED PATIENTS
Chaudhari, P.
Yang, H.
Zhou, Z. Y.
Patel, C.
Wu, E. Q.
VALUE IN HEALTH, 2013, 16 (03) : A83 - A84
[25] Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States
Yang H.
Chaudhari P.
Zhou Z.-Y.
Wu E.Q.
Patel C.
Horn D.L.
Applied Health Economics and Health Policy, 2014, 12 (1) : 85 - 93
[26] Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections
Drew, Richard
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2006, 27 : S36 - S44
[27] Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
Walsh, TJ
Hiemenz, JW
Seibel, NL
Perfect, JR
Horwith, G
Lee, L
Silber, JL
DiNubile, MJ
Reboli, A
Bow, E
Lister, J
Anaissie, EJ
CLINICAL INFECTIOUS DISEASES, 1998, 26 (06) : 1383 - 1396
[28] Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies
Cahuayme-Zuniga, Lizbeth
Lewis, Russell E.
Mulanovich, Victor E.
Kontoyiannis, Dimitrios P.
MEDICAL MYCOLOGY, 2012, 50 (05) : 543 - 548
[29] Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients
Herbrecht, R
Auvrignon, A
Andrès, E
Guillemain, R
Suc, A
Eyer, D
Pailler, C
Letscher-Bru, V
Leverger, G
Schaison, G
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2001, 20 (02) : 77 - 82
[30] Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients
G Noskin
L Pietrelli
M Gurwith
R Bowden
Bone Marrow Transplantation, 1999, 23 : 697 - 703

← 1 2 3 4 5 →